Brands
Eternal Limited posts steady Q3 revenue and profit numbers
NEW DELHI: Eternal Limited, formerly known as Zomato, has released its financial results for the third quarter and nine months ending 31 December 2025, reporting steady growth across key segments.
For the quarter, consolidated total income reached Rs 16,663 crore, generating a profit before tax of Rs 170 crore. Net profit after tax was Rs 102 crore, while total comprehensive income, factoring in other gains and losses, stood at Rs 130 crore. Over the nine-month period, consolidated income surged to Rs 38,126 crore, with profit before tax at Rs 387 crore and net profit at Rs 192 crore. Total comprehensive income for the nine months came in at Rs 12 crore, reflecting adjustments from equity instruments, foreign exchange, and remeasurements of employee benefit plans.
On a standalone basis, Eternal reported total income of Rs 3,308 crore in Q3 and Rs 9,212 crore over nine months, with net profit aligning with consolidated results at Rs 102 crore for the quarter and Rs 192 crore for the nine months. Earnings per share for the quarter were Rs 0.11, basic and diluted, and Rs 0.21 basic and Rs 0.20 diluted for the nine-month period.
Segment-wise, India food delivery recorded Rs 2,676 crore in Q3 and Rs 7,422 crore for the nine months, while Blinkit quick commerce generated Rs 12,256 crore in the quarter and Rs 24,547 crore over nine months. Hyperpure supplies contributed Rs 1,170 crore in Q3 and Rs 4,388 crore over the nine months.
Total expenses for the quarter were Rs 16,493 crore, driven by stock purchases of Rs 10,076 crore, delivery and logistics costs of Rs 2,376 crore, employee benefits of Rs 914 crore, advertising and promotions of Rs 937 crore, and depreciation and amortisation of Rs 439 crore. Over nine months, expenses amounted to Rs 37,739 crore against total income of Rs 38,126 crore.
The results indicate a steady performance across Eternal’s core business lines, particularly in food delivery and quick commerce, even as the company navigates regulatory challenges and integrates acquisitions into its operations.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
